Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Chemerin (RARRES2 [retinoic acid receptor responder 2], TIG2 [tazarotene induced gene 2]) is a multifunctional cytokine initially described in skin cultures upon exposure to the synthetic retinoid tazarotene. Its secreted pro-form, prochemerin, is widely expressed, found systemically, and is readily converted into active chemerin by various proteases. Subsequent studies elucidated major roles of chemerin as both a leukocyte chemoattractant as well as an adipokine. Chemerin’s main chemotactic receptor, the G-protein coupled receptor CMKLR1, is expressed on macrophages, dendritic, and NK cells. With respect to its role in immunology, chemerin mediates trafficking of these cells to sites of inflammation along its concentration gradient, and likely helps coordinate early responses, as it has been shown to have antimicrobial and angiogenic properties, as well. Recently, there has been mounting evidence that chemerin is an important factor in various cancers. As with its role in immune responses – where it can act as both a pro- and anti-inflammatory mediator – the potential functions or correlations chemerin has in or with cancer appears to be context dependent. Most studies, however, suggest a downregulation or loss of chemerin/RARRES2 in malignancies compared to the normal tissue counterparts. Here, we perform a comprehensive review of the literature to date and summarize relevant findings in order to better define the roles of chemerin in the setting of the tumor microenvironment and tumor immune responses, with an ultimate focus on the potential for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Wittamer, V., Franssen, J.-D., Vulcano, M., Mirjolet, J.-F., Le Poul, E., Migeotte, I., Brézillon, S., Tyldesley, R., Blanpain, C., Detheux, M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030382 · Cited by 888
Polakis, P. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008052 · Cited by 847 · cited 1×
“Aberrant activation of the Wnt/β-catenin pathway is common in many other cancer types, such as breast cancer, lung cancer, hepatocellular carcinoma, and squamous cell carcinoma (47).”
BackgroundAdrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Tissier, F., Cavard, C., Groussin, L., Perlemoine, K., Fumey, G., Hagneré, A.-M., René-Corail, F., Jullian, E., Gicquel, C., Bertagna, X., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0593 · Cited by 474
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451 · cited 1×
“In fact, the potential risk of ACC is considered the standard for adrenalectomy in patients with adrenal incidentalomas (38).”
BackgroundSynthetic chemerin-derived peptides suppress inflammation through ChemR23
Cash, J. L., Hart, R., Russ, A., Dixon, J. P. C., Colledge, W. H., Doran, J., Hendrick, A. G., Carlton, M. B. L., & Greaves, D. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071601 · Cited by 372 · cited 1×
“Additionally, studies have detected CMKLR1 in breast tissue (52).”
BackgroundChemerin and its receptors in leukocyte trafficking, inflammation and metabolism
Bondue, B., Wittamer, V., & Parmentier, M. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.11.004 · Cited by 294 · cited 2×
“In the literature, CMKLR1 is usually discussed as the primary receptor for chemerin interaction, while CCRL2 is described to participate in various functions by binding and presenting chemerin in a non-signaling manner to establish concentration gradients (4, 5).”
BackgroundGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Wischermann, K., Popp, S., Moshir, S., Scharfetter-Kochanek, K., Wlaschek, M., de Gruijl, F., Hartschuh, W., Greinert, R., Volkmer, B., Faust, A., et al. (2008) · Oncogene · doi:10.1038/onc.2008.70 · Cited by 99 · cited 1×
“Affecting the elderly at disproportionately higher rates, CSCC is mainly caused by chronic exposure to ultraviolet radiation (114, 115).”
Background
Cited by
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Chen, D., Zhang, X., Li, Z., & Zhu, B. (2021) · Theranostics · doi:10.7150/thno.51777 · Cited by 390
Zhang, X., Tian, L., Majumdar, A., & Scheller, E. L. (2024) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2024.tb00300.x · Cited by 18
Metadata
- Authors
- Shin, W. J., Zabel, B. A., & Pachynski, R. K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-30
- Volume
- 9
- Pages
- 2772-2772
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2902283448
- Cited by
- 75
- References
- 11
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention. https://app.cochat.ai/papers/10.3389/fimmu.2018.02772
- The paper
- Shin, W. J., Zabel, B. A., & Pachynski, R. K. (2018). Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.02772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.